Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 14/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 14/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.58 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296157 | 0.90 | PIK3CD (0.70) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL1750491 | 0.83 | PIK3CD (0.53) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL28821909 | 0.81 | PIK3CD (0.48) | PIK3CDPIK3CBPIK3CGPIK3CA | |
| SCHEMBL28299587 | 0.80 | PIK3CD (0.47) | PIK3CDPIK3CBPIK3CGPIK3CA | |
| SCHEMBL28782653 | 0.78 | CSNK2A1 (0.74) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL300868 | 0.75 | PIK3CD (0.71) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL297655 | 0.73 | PIK3CD (0.64) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL300821 | 0.72 | PIK3CD (0.65) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL29793901 | 0.72 | PIK3CD (0.65) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 | |
| SCHEMBL11939631 | 0.71 | PIK3CD (0.82) | PIK3CDPIK3CBPIK3CGPIK3CACSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383634-B2 | Methods of treatment using heteroaryl compounds and compositions thereof | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110224217-A1 | METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF | SIGNAL PHARMACEUTICALS, LLC | 2011-09-15 | — | — | US | disclosed |
| US-7968556-B2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-06-28 | — | — | US | disclosed |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224217-A1 | METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF | JAK2, CHEK2, PHKG1 | PIK3CD 649/4885PIK3CB 267/4885PIK3CG 821/4885 |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, SRC | PIK3CD 569/4885PIK3CB 267/4885PIK3CG 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.